Analysis of whether Seripase (BRINEURA) is an imported drug or a domestic drug and its market supply situation

Seripalase (BRINEURA) is a recombinant lysosomal enzyme preparation used to treat gangliosidosis (CLN2 type pediatric leukemic degenerative disease). The drug is a targeted enzyme replacement therapy that slows down the degenerative progression of the nervous system by supplementing the missing TTP1 enzyme in the body. It has important clinical significance for children with CLN2-type diseases. Due to its complex production process, it is a high-end biopharmaceutical product.

In the domestic market, seripalase has not yet been officially launched, so patients cannot obtain the drug directly through domestic hospitals or pharmacies. Current domestic treatment options mainly rely on imports through formal overseas channels, usually through professional drug agents or cross-border medical services. This means that patients and families need to follow strict laws and regulations when obtaining medicines to ensure that medicines come from legal sources and meet transportation and storage conditions.

In terms of price, seripase is a high-value imported biopharmaceutical. Taking overseas markets as an example, the price of each bottle of 150mg/5ml is 16,190.17 US dollars, and is usually sold in two bottles per package, with a total price of about 32,380.33USD. Because this drug is a rare disease treatment drug, it is expensive and is not currently included in the medical insurance system. Therefore, the financial burden is large, and families need to consider financing and payment strategies in advance when designing medical plans.

Generally speaking, seripase (BRINEURA) is an imported drug and has not yet been marketed in China. Patients need to rely on overseas formal channels when using it, and combine dosage and treatment plan management with the guidance of clinical experts. If it is launched domestically or is included in medical insurance in the future, it will greatly improve drug accessibility and patients' affordability. At this time, families and doctors need to fully evaluate the clinical benefit, logistics and economic feasibility of treatment to ensure safe and continuous treatment.

Reference materials:https://www.drugs.com/

xa0